English | Español

Innovent Biologics, Inc.
Press release submission | Jul 3, 2022

Innovent Announces First Patient Dosed in a Phase 2 Clinical study of IBI112 (IL-23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Active Ulcerative Colitis
Press release submission | Mar 20, 2019

INNOVENT BIOLOGICS, INC. : Announces First Patient Dosed in a Phase IIa Clinical Study of IBI306, an Anti-PCSK9 Monoclonal Antibody
Press release submission | Feb 27, 2019

INNOVENT BIOLOGICS, INC.: First Patient Dosed in a Clinical Trial of Tyvyt® (Sintilimab injection) in Combination with IBI305 as First Line Treatment for Patients with Advanced Hepatocellular Carcinoma

Trending
+ Pharmaceuticals
Patient Daily | Jun 18, 2025

ENT specialist on acid reflux: ‘You actually have a structural issue that may predispose you to sinusitis’
+ Pharmaceuticals
Patient Daily | Jun 16, 2025

American Consumer Institute questions hospital use of 340B Drug Pricing Program
+ Pharmaceuticals
Patient Daily | Jun 13, 2025

Data scientist: ‘340B sales growth was 115.5% higher than the growth of non-340B sales in 2023’
+ Pharmaceuticals
Patient Daily | Jun 19, 2025

Patients Come First spokesperson on 340B reform: ‘Americans deserve a system that prioritizes patients first, not pharmacy middlemen’